APOE and Alzheimer disease: Given these potential differences in treatment efficacy for APOE4+ vs. APOE4− AD patients, it is important not only to elucidate any overall cognitive and pathological heterogeneity between these two groups, but also to understand the underlying mechanisms that may drive this heterogeneity.